Fayez Sarofim & Co
ABBV icon

Fayez Sarofim & Co’s AbbVie ABBV Stock Holding History

Fayez Sarofim & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$599M Buy
2,756,256
+172,048
+7% +$38.2M 1.53% 21
2025
Q4 		$590M Buy
2,584,208
+420,903
+19% +$95.9M 1.42% 22
2025
Q3 		$501M Sell
2,163,305
-4,690
-0.2% -$955K 1.16% 28
2025
Q2 		$402M Buy
2,167,995
+1,726
+0.1% +$321K 0.97% 30
2025
Q1 		$454M Sell
2,166,269
-39,919
-2% -$7.76M 1.13% 29
2024
Q4 		$392M Buy
2,206,188
+153,294
+7% +$28.2M 0.95% 31
2024
Q3 		$405M Buy
2,052,894
+24,061
+1% +$4.49M 1.03% 30
2024
Q2 		$348M Buy
2,028,833
+103,709
+5% +$17.2M 0.94% 31
2024
Q1 		$351M Sell
1,925,124
-8,122
-0.4% -$1.4M 1.04% 30
2023
Q4 		$337M Sell
1,933,246
-65,209
-3% -$9.51M 1.03% 29
2023
Q3 		$298M Buy
1,998,455
+87,539
+5% +$12.9M 1.01% 32
2023
Q2 		$257M Sell
1,910,916
-163,187
-8% -$23.9M 0.9% 33
2023
Q1 		$331M Buy
2,074,103
+53,400
+3% +$8.16M 1.16% 30
2022
Q4 		$327M Sell
2,020,703
-181,557
-8% -$27.8M 1.21% 30
2022
Q3 		$296M Sell
2,202,260
-4,715
-0.2% -$677K 1.17% 31
2022
Q2 		$338M Sell
2,206,975
-8,973
-0.4% -$1.37M 1.23% 30
2022
Q1 		$359M Buy
2,215,948
+8,113
+0.4% +$1.18M 1.14% 32
2021
Q4 		$299M Buy
2,207,835
+13,674
+0.6% +$1.62M 0.9% 36
2021
Q3 		$237M Sell
2,194,161
-215,203
-9% -$24.6M 0.78% 42
2021
Q2 		$271M Sell
2,409,364
-531,664
-18% -$59.9M 0.91% 36
2021
Q1 		$318M Sell
2,941,028
-118,969
-4% -$12.7M 1.17% 31
2020
Q4 		$328M Sell
3,059,997
-121,006
-4% -$11.6M 1.26% 30
2020
Q3 		$279M Sell
3,181,003
-250,243
-7% -$23.6M 1.19% 29
2020
Q2 		$337M Buy
3,431,246
+384,878
+13% +$33.9M 1.55% 20
2020
Q1 		$232M Sell
3,046,368
-146,775
-5% -$12.5M 1.43% 28
2019
Q4 		$283M Sell
3,193,143
-95,360
-3% -$7.92M 1.36% 29
2019
Q3 		$249M Sell
3,288,503
-62,150
-2% -$4.26M 1.28% 30
2019
Q2 		$244M Sell
3,350,653
-53,203
-2% -$4.18M 1.26% 29
2019
Q1 		$274M Sell
3,403,856
-31,924
-0.9% -$2.61M 1.45% 27
2018
Q4 		$317M Sell
3,435,780
-42,483
-1% -$3.74M 1.91% 16
2018
Q3 		$329M Sell
3,478,263
-56,550
-2% -$5.36M 1.72% 15
2018
Q2 		$328M Sell
3,534,813
-87,843
-2% -$8.58M 1.76% 14
2018
Q1 		$343M Buy
3,622,656
+45,297
+1% +$4.98M 1.86% 14
2017
Q4 		$346M Sell
3,577,359
-129,544
-3% -$12.2M 1.79% 16
2017
Q3 		$329M Sell
3,706,903
-3,269
-0.1% -$249K 1.73% 16
2017
Q2 		$269M Sell
3,710,172
-91,372
-2% -$6.14M 1.44% 21
2017
Q1 		$248M Sell
3,801,544
-401,423
-10% -$25.2M 1.35% 22
2016
Q4 		$263M Sell
4,202,967
-180,093
-4% -$11M 1.45% 22
2016
Q3 		$277M Sell
4,383,060
-127,384
-3% -$8.25M 1.5% 21
2016
Q2 		$280M Sell
4,510,444
-3,715
-0.1% -$226K 1.53% 20
2016
Q1 		$258M Buy
4,514,159
+89,220
+2% +$4.97M 1.48% 19
2015
Q4 		$261M Sell
4,424,939
-88,372
-2% -$5.09M 1.5% 18
2015
Q3 		$246M Sell
4,513,311
-210,542
-4% -$13.7M 1.42% 18
2015
Q2 		$318M Sell
4,723,853
-206,693
-4% -$13.5M 1.62% 15
2015
Q1 		$288M Sell
4,930,546
-100,912
-2% -$6.1M 1.41% 18
2014
Q4 		$330M Sell
5,031,458
-178,407
-3% -$11.2M 1.56% 15
2014
Q3 		$301M Sell
5,209,865
-86,841
-2% -$4.82M 1.4% 20
2014
Q2 		$299M Sell
5,296,706
-39,709
-0.7% -$2.08M 1.37% 23
2014
Q1 		$275M Sell
5,336,415
-93,150
-2% -$4.71M 1.31% 25
2013
Q4 		$287M Buy
+5,429,565
New +$267M 1.33% 23
2013
Q2 		$231M Buy
+5,579,640
New +$244M 1.16% 29

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co's ABBV Position: Q1 2026 in Review

Fayez Sarofim & Co increased its AbbVie (ABBV) stake by 6.7% in Q1 2026, buying an estimated $38.2M and bringing the position to 2,756,256 shares worth $599M. The position accounts for 1.53% of the portfolio, ranked #21.

Fayez Sarofim & Co first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fayez Sarofim & Co held 2,756,256 shares of AbbVie worth $599M as of Q1 2026.
  • Fayez Sarofim & Co bought 172,048 AbbVie shares in Q1 2026, an estimated $38.2M.
  • AbbVie made up 1.53% of Fayez Sarofim & Co's portfolio in Q1 2026, its #21 holding.
  • Fayez Sarofim & Co first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.